These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

672 related items for PubMed ID: 26948652

  • 1. Prognostic value of metabolic tumour volume and total lesion glycolysis in 18F-FDG PET/CT scans in locally advanced breast cancer staging.
    Jiménez-Ballvé A, García García-Esquinas M, Salsidua-Arroyo O, Serrano-Palacio A, García-Sáenz JA, Ortega Candil A, Fuentes Ferrer ME, Rodríguez Rey C, Román-Santamaría JM, Moreno F, Carreras-Delgado JL.
    Rev Esp Med Nucl Imagen Mol; 2016; 35(6):365-372. PubMed ID: 26948652
    [Abstract] [Full Text] [Related]

  • 2. The correlation of 18F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer.
    Qu YH, Long N, Ran C, Sun J.
    Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
    Calles-Sastre L, Mucientes-Rasilla J, San-Frutos Llorente LM, Royuela A, Garcia-Espantaleón Navas M, Herrero Gámiz S, Pérez-Medina T.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019 Mar; 38(1):17-21. PubMed ID: 30366731
    [Abstract] [Full Text] [Related]

  • 4. [The relationship between (18)F-FDG PET/CT metabolic parameters and clinicopathological features of breast cancer].
    Tang B, Zhang Y, Zhou J, Xu Y, Li TR, Ding CY.
    Zhonghua Zhong Liu Za Zhi; 2017 Apr 23; 39(4):280-285. PubMed ID: 28550668
    [Abstract] [Full Text] [Related]

  • 5. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
    Son SH, Lee SW, Jeong SY, Song BI, Chae YS, Ahn BC, Lee J.
    AJR Am J Roentgenol; 2015 Oct 23; 205(4):878-85. PubMed ID: 26204115
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan 23; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 7. Metabolic parameters of [18F]FDG PET-CT before and after radiotherapy may predict survival and recurrence in cervical cancer.
    Markus M, Sartor H, Bjurberg M, Trägårdh E.
    Acta Oncol; 2023 Feb 23; 62(2):180-188. PubMed ID: 36815676
    [Abstract] [Full Text] [Related]

  • 8. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.
    Satoh K, Patel D, Dieckmann W, Nilubol N, Kebebew E.
    Ann Surg Oncol; 2015 Dec 23; 22 Suppl 3():S714-20. PubMed ID: 26282908
    [Abstract] [Full Text] [Related]

  • 9. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline 18F-FDG PET/CT in breast cancer with neoadjuvant chemotherapy indication.
    Garcia-Vicente AM, Pérez-Beteta J, Amo-Salas M, Molina D, Jimenez-Londoño GA, Soriano-Castrejón AM, Pena Pardo FJ, Martínez-González A.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018 Dec 23; 37(2):73-79. PubMed ID: 29102649
    [Abstract] [Full Text] [Related]

  • 10. Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?
    Evangelista L, Cervino AR, Ghiotto C, Saibene T, Michieletto S, Fernando B, Orvieto E, Guarneri V, Conte P.
    Eur J Nucl Med Mol Imaging; 2015 Oct 23; 42(11):1648-1655. PubMed ID: 26025244
    [Abstract] [Full Text] [Related]

  • 11. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
    Lee JW, Kang CM, Choi HJ, Lee WJ, Song SY, Lee JH, Lee JD.
    J Nucl Med; 2014 Jun 23; 55(6):898-904. PubMed ID: 24711649
    [Abstract] [Full Text] [Related]

  • 12. Alternative volumetric PET pjmirometers for evaluation of breast cancer cases with 18F-FDG PET/CT imaging: Metabolic tumour volume and total lesion glycolysis.
    Arslan E, Can Trabulus D, Mermut Ö, Şavlı TC, Çermik TF.
    J Med Imaging Radiat Oncol; 2021 Feb 23; 65(1):38-45. PubMed ID: 33084216
    [Abstract] [Full Text] [Related]

  • 13. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
    Son SH, Kang SM, Jeong SY, Lee SW, Lee SJ, Lee J, Ahn BC.
    Clin Nucl Med; 2016 Jun 23; 41(6):e266-73. PubMed ID: 27055144
    [Abstract] [Full Text] [Related]

  • 14. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH, Cho A, Yun M, Choi YD, Rha SY, Kang WJ.
    Clin Nucl Med; 2017 May 23; 42(5):e235-e241. PubMed ID: 28288043
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW, Oh JS, Roh JL, Kim JS, Choi SH, Nam SY, Kim SY.
    Eur J Nucl Med Mol Imaging; 2015 Aug 23; 42(9):1353-61. PubMed ID: 26067088
    [Abstract] [Full Text] [Related]

  • 16. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.
    Nakajima N, Kataoka M, Sugawara Y, Ochi T, Kiyoto S, Ohsumi S, Mochizuki T.
    Int J Radiat Oncol Biol Phys; 2013 Nov 15; 87(4):738-46. PubMed ID: 24064322
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of FDG-PET and DWI in breast cancer.
    Kitajima K, Miyoshi Y, Yamano T, Odawara S, Higuchi T, Yamakado K.
    Ann Nucl Med; 2018 Jan 15; 32(1):44-53. PubMed ID: 29134565
    [Abstract] [Full Text] [Related]

  • 18. Metabolic Tumor Burden Assessed by Dual Time Point [18F]FDG PET/CT in Locally Advanced Breast Cancer: Relation with Tumor Biology.
    Garcia-Vicente AM, Pérez-Beteta J, Pérez-García VM, Molina D, Jiménez-Londoño GA, Soriano-Castrejón A, Martínez-González A.
    Mol Imaging Biol; 2017 Aug 15; 19(4):636-644. PubMed ID: 27981471
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with 18F-FDG PET/CT, in patients with diffuse large cell B-cell lymphoma.
    Guzmán Ortiz S, Mucientes Rasilla J, Vargas Núñez JA, Royuela A, Navarro Matilla B, Mitjavila Casanovas M.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020 Aug 15; 39(6):340-346. PubMed ID: 32646783
    [Abstract] [Full Text] [Related]

  • 20. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A, Duan F, Snyder BS, Wei B, Houshmand S, Khiewvan B, Opanowski A, Simone CB, Siegel BA, Machtay M, Alavi A.
    Eur J Nucl Med Mol Imaging; 2017 Nov 15; 44(12):1969-1983. PubMed ID: 28689281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.